fbpx

Nyheder

Lundbeckfonden Ventures nyheder

Lead ‘OncoMimics’ candidate EO2401 planned to start first clinical trials for Glioblastoma and Adrenal Tumors during mid-2020 Paris, France and Cambridge, MA, USA – June 25, 2020 ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge  of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today announces a new financing totaling €46.3 million ($52.6million) to...
SNF472 selectively inhibits pathological calcification by binding to hydroxyapatite crystals Palma, Spain and San Diego, USA, 25 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that data examining the mechanism of action of SNF472, Sanifit’s lead compound in development, has been published in the British Journal of...
•    The EU bank will support Palma-based Sanifit in its work to develop cutting-edge solutions in biomedical research. •    The venture debt operation is supported by the Investment Plan for Europe. Palma, Spain and San Diego, USA, 6 August 2020 – The European Investment Bank (EIB) is set to support the development of new treatments...
Newly appointed VP of Business Development and SVP of Clinical Development each bring to Sanifit over 20 years of industry experience Palma, Spain and San Diego, USA, 01 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, is delighted to announce two new appointments to its Executive leadership team, with...
Cambridge, UK and Indianapolis, US –  1 June 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a commercial-stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures or chemotherapy, announces an amendment to the terms...
Paris, France and Cambridge, MA, USA – August 5, 2020   ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, announces that Pierre Belichard, CEO, and Christophe Bonny, CSO, will participate in the BTIG Virtual Biotechnology Conference 2020 which will take place August 10-11th 2020.  ...
Cambridge, UK and Indianapolis, US – 8 May 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces...
Cambridge, UK and Indianapolis, US – 7 May 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 7 April 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the...
1 2 3 4 67

Lundbeckfonden Ventures

Nyheder

Enterome initiates first clinical trial with EO2401 – an innovative microbiome-antigen (‘OncoMimic’) based cancer immunotherapy candidate targeting aggressive brain cancer
30. juli 2020
Acacia Pharma Advances Preparations for US Launch of BARHEMSYS® Second API Supplier for BARHEMSYS® Receives FDA Approval
27. juli 2020
Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease
20. juli 2020